The Drug-Induced Respiratory Disease Website and App

COVID19 (SARS-CoV2) vaccination/vaccine

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

I.b

Pneumonitis (interstitial lung disease/ILD)

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I.y

Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I.ad

Radiation recall pneumonitis

I.ay

Unilateral interstitial lung disease

I.bc

Progression or exacerbation of preexisting/underlying rheumatoid arthritis-associated ILD

II - Pulmonary edema - Acute lung injury - ARDS

II.b

ARDS - Acute lung injury

II.d

Pulmonary edema, cardiogenic

III - Pulmonary/alveolar/airway hemorrhage/bleeding

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

III.m

Coagulopathy

IV - Airway involvement

IV.a

Bronchospasm - Wheezing - Asthma

IV.ac

Exacerbation or deterioration of preexisting asthma

VI - Pulmonary vasculopathy

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

VI.b

Pulmonary arterial hypertension

VI.ac

Pulmonary infarction

IX - Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r

Myasthenia gravis - Myasthenic-like syndrome

IX.y

A flare or relapse of preexisting myasthenia gravis

IX.ab

Guillain-Barré (or GB-like) syndrome (w/wo ARF)

X - Systemic/Distant conditions, syndromes and reactions

X.b

Antiphospholipid antibodies w/wo the APL syndrome

X.d

Lupus - Lupus syndrome (see also Vd)

X.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

X.h

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X.j

Myopathy-Myositis-Polymyositis (see also under Xba)

X.m

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X.s

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X.aj

Polyarteritis nodosa-like condition

X.be

A flare of preexisting immune-mediated systemic/rheumatic disease

X.bf

Anti-Jo-1 syndrome

X.bg

IgA vasculitis

X.bh

Protracted, prolonged anaphylaxis

X.bj

Anti Jo1 syndrome

XI - Miscellaneous

XI.b

Chest pain (acute or subacute), lone or prominent

XII - Cardiovascular involvement / toxicity

XII.a

Left or biventricular dysfunction/failure

XII.c

Pericardial effusion (w/wo tamponade)

XII.d

Myocarditis (can be fulminant)

XII.e

Takotsubo (stress) cardiomyopathy

XII.g

Coronary artery disease (acute) - Myocardial ischemia/infarction

XII.h

Eosinophilic myocarditis

XII.k

Constrictive pericarditis - Pericardial thickening

XII.l

Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII.m

Cardiac- cardiorespiratory/pulmonary arrest

XII.q

Pericarditis (see also under XIIc)

XII.ai

Cardiotoxicity

XII.bf

Myopericarditis (see under XIIc/d/g)

XII.cc

Relapse of previously diagnosed myocarditis

XV - Pathology

XV.a

Path: NSIP-cellular pattern (see also Ia, Ib)

XV.c

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XVI - Imaging

XVI.b

Imaging: Ground-glass opacities (GGO) / shadowing

XVI.c

Imaging: A mosaic pattern of attenuation

XVI.ay

Imaging: Asymmetrical, predominantly unilateral involvement

XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a

BAL: An excess proportion of lymphocytes

XIX.c

BAL: An excess proportion of eosinophils